Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reimportation Advocates Have Support Of “Rogue” Pfizer Exec

Executive Summary

The pharmaceutical industry's experience with parallel trade in Europe demonstrates that safety concerns should not prevent Rx importation in the U.S., according to a Pfizer exec

You may also be interested in...



Pfizer fires “rogue” exec

Pfizer terminates VP-Marketing Peter Rost Dec. 1. Rost made headlines in 2004 when he publicly voiced support for pharmaceutical importation (1"The Pink Sheet" Sept. 27, 2004, p. 15). His termination follows the unsealing of a qui tam lawsuit in which Rost alleged Pharmacia violated the False Claims Act by promoting the human growth hormone product Genotropin off-label prior to Pfizer's acquisition of the firm in 2003. The Boston U.S. Attorney chose not to intervene on Rost's behalf in the case although governmental investigations into other aspects of Pharmacia's Genotropin promotion are ongoing, the company says...

Pfizer fires “rogue” exec

Pfizer terminates VP-Marketing Peter Rost Dec. 1. Rost made headlines in 2004 when he publicly voiced support for pharmaceutical importation (1"The Pink Sheet" Sept. 27, 2004, p. 15). His termination follows the unsealing of a qui tam lawsuit in which Rost alleged Pharmacia violated the False Claims Act by promoting the human growth hormone product Genotropin off-label prior to Pfizer's acquisition of the firm in 2003. The Boston U.S. Attorney chose not to intervene on Rost's behalf in the case although governmental investigations into other aspects of Pharmacia's Genotropin promotion are ongoing, the company says...

Vioxx Shock Is Latest Headache For Rx Stocks; Is Election Day A Cure?

Pfizer's $27 bil. devaluation during the third quarter is strong evidence that Wall Street's aversion to drug stocks goes far beyond the Vioxx withdrawal

Related Content

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel